The cutaneous toxicity of the epidermal growth factor receptor inhibitors, such as erlotinib, is associated with a wide range of manifestations, such as papulopustular eruptions, xerosis, paronychia, and changes in the growth pattern of hair and nails. Hair manifestations are seen in 10%-20% of the patients. A female patient taking erlotinib for lung cancer for 8 months noticed that her scalp hair became rough on palpation and that her eyelashes were elongated. Some scalp hairs were cut and proximal and distal portions were examined in natura with scanning electron microscopy. Torsions and important grooving were seen in the proximal portions, but not in distal hair portions. Erlotinib-induced hair changes are pili torti et canaliculi.
INTRODUCTION
S mall-molecule inhibitors of epidermal growth factor receptor (EGFR), such as erlotinib, have been used in the treatment of solid tumors, including non-small cell lung cancer and in the treatment of advanced nonoperable pancreatic carcinoma. [1] The therapeutic aim of erlotinib is the inhibition of EGFR, which is overexpressed in some tumors and plays an important role in the signaling pathways, being involved in the proliferation of malignant cells, migration, adhesion, in the induction of angiogenesis, and in apoptosis inhibition. [1, 2] Erlotinib is well tolerated, but shows some adverse effects, such as diarrhea and cutaneous eruptions. [3] Erlotinib also acts by inhibiting the expression of EGFR in healthy tissues, for example, in the basal and suprabasal epidermal layers, sebaceous glands, and the outer root sheath of hair follicles. [4] The cutaneous toxicity of the EGFR inhibitors, such as erlotinib, is associated with a wide range of manifestations, such as papulopustular eruptions, xerosis, paronychia, and changes in the growth pattern of hair and nails, [5] resulting in significant impact on life quality. [6] Hair manifestations are seen in 10%-20% of the patients. [6, 7] Other EGFR inhibitors, such as gefitinib, have a similar side effect profile. [6] 
CASE REPORT
We examined a 60-year-old female patient, with lung carcinoma, taking erlotinib for 8 months. She noticed that her eyelashes became elongated, thicker, and lost its natural curvature [ Figure 1 ]. She noticed also that the emerging proximal hair became rough on palpation, but not the distal portion. She had some paronychia and an acneiform eruption on her trunk and arms. Some scalp hairs were carefully cut, in order to avoid artifacts, and the proximal and distal portions were examined in natura with scanning electron microscopy.
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Scanning electron microscopy of the proximal scalp hair portion showed important grooving, associated in some hairs with torsion [ Figure 2a ]; some angulation of the hair shafts was also observed [ Figure 2b ]. Single [ Figure 2c ] and double grooving were seen [ Figure 2d ]. The distal portion of the same examined hairs, which were not yet clinically affected, showed only some weathering signs, with light irregularity of the cuticula [Figure 2e ], without grooving or torsion.
DISCUSSION
Similar erlotinib-induced hair changes with elongated and thicker eyelashes were already reported; [5] some other cases were described as hair shaft textural changes, [6] [7] [8] androgenetic-like frontal alopecia, [9] and eyelashes trichomegaly. [8] These ultrastructural findings document the hair changes induced by antiepidermal growth factor treatment, which are in some extent similar to those found in some genetic conditions belonging to the uncombable hair spectrum. [10] 
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